Guangzhou Beixiu Biotechnology

Guangzhou Beixiu Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the research and development of advanced cell therapies. The company primarily focuses on chimeric antigen receptor T-cell (CAR-T) technology for the treatment of hematological malignancies and potentially solid tumors. Its lead program, BX-C001, is an autologous CD19-targeted CAR-T cell therapy currently in Phase 1 clinical trials for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Beixiu Biotech operates out of the Guangzhou International Bio-island, leveraging a specialized R&D and manufacturing infrastructure to advance its immunotherapy pipeline. The company aims to develop high-quality, affordable cell therapy products to address unmet medical needs in oncology.